Longitudinal combined 11C UCB J and 18F FE PE2I PET imaging of presynaptic terminal loss in early Parkinson’s disease.
Objective: To longitudinally assess presynaptic terminal loss in vivo over a 2-year period in people with early Parkinson’s disease (PD). Background: Imaging tools that allow…Brain glia activation and peripheral inflammation in Parkinson’s disease: a PET study
Objective: Abnormal activation of immune system is an important pathogenesis of Parkinson's disease, but the relationship between peripheral inflammation, central glia activation and dopaminergic degeneration…Widespread loss of presynaptic terminal marker SV2A in early Huntington’s disease.
Objective: To assess synaptic damage in early stages of Huntington’s disease (HD) in vivo. Background: Synaptic damage has long been suspected to play a major…Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy
Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…Movement Disorders After Bariatric Surgeries – Case Series
Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation
Objective: To investigate the time course of modifications in dopaminergic terminals during the premotor phase in LRRK2 genetically determined Parkinson’s disease (PD). Background: Increased dopamine…DNAJC13 in Parkinson’s disease; characterization of the p.N855S knock-in mouse model
Objective: To study the effects of DNAJC13 p.Asn855Ser mutant gene dysfunction in a physiological context, and to help define molecular mechanisms for disease, using a…Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up
Objective: To examine the clinical and biological characteristics of participants with scans without evidence of dopaminergic deficit (SWEDD) during a two-year follow-up. Background: Study participants…Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease
Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease. Background: Recent work has shown loss of PDE10A expression…Age-related failure in compensatory mechanisms and its relation to the Parkinson phenotype: evidence from a SPECT study in early and late-onset PD
Objective: To investigate if a less prominent dopaminergic dysfunction on 123I-ioflupane SPECT imaging (DaTSCAN) despite a more severe motor phenotype in Late Onset Parkinson’s Disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.